Labit-Le Bouteiller C, Jamme M F, David M, Silve S, Lanau C, Dhers C, Picard C, Rahier A, Taton M, Loison G, Caput D, Ferrara P, Lupker J
Sanofi Recherche, Centre de Labège, France.
Eur J Biochem. 1998 Sep 1;256(2):342-9. doi: 10.1046/j.1432-1327.1998.2560342.x.
SR31747A is a new sigma ligand exhibiting immunosuppressive properties and antiproliferative activity on lymphocyte cells. Only two subtypes of sigma receptor, namely the sigma1 receptor and emopamil-binding protein, have been characterised molecularly. Only the sigma1 receptor has been shown to bind (Z)N-cyclohexyl-N-ethyl-3-(3-chloro4-cyclohexylphenyl)pro pen-2-ylamine hydrochloride (SR31747A) with high affinity. It was demonstrated that the SR31747A effect on the inhibition of T-cell proliferation was consistent with a sigma1 receptor-mediated event. In this report, binding experiments and sterol isomerase assays, using recombinant yeast strains, indicate that the recently cloned emopamil-binding protein is a new SR31747A-binding protein whose activity is inhibited by SR31747A. Sterol analyses reveal the accumulation of a delta8-cholesterol isomer at the expense of cholesterol in SR31747A-treated cells, suggesting that cholesterol biosynthesis is inhibited by SR31747A at the delta8-delta7 sterol isomerase step in animal cells. This observation is consistent with a sterol isomerase role of the emopamil-binding protein in the cholesterol biosynthetic pathway in animal cells. In contrast, there is no evidence for such a role of the sigma1 receptor, in spite of the structural similarity shared by this protein and yeast sterol isomerase. We have found that SR31747A also exerts anti-proliferative effects at nanomolar concentrations on various established cell lines. The antiproliferative activity of SR31747A is reversed by cholesterol. Sterol-isomerase overproduction enhances resistance of CHO cells. This last observation strongly suggests that sterol isomerase is implicated in the antiproliferative effect of the drug in established cell lines.
SR31747A是一种新型西格玛配体,对淋巴细胞具有免疫抑制特性和抗增殖活性。目前仅在分子水平上鉴定出两种西格玛受体亚型,即西格玛1受体和伊莫帕明结合蛋白。仅显示西格玛1受体能与盐酸(Z)N-环己基-N-乙基-3-(3-氯-4-环己基苯基)丙烯-2-胺(SR31747A)高亲和力结合。已证明SR31747A对T细胞增殖的抑制作用与西格玛1受体介导的事件一致。在本报告中,使用重组酵母菌株进行的结合实验和甾醇异构酶测定表明,最近克隆的伊莫帕明结合蛋白是一种新的SR31747A结合蛋白,其活性受到SR31747A的抑制。甾醇分析显示,在经SR31747A处理的细胞中,以胆固醇为代价积累了δ8-胆固醇异构体,这表明在动物细胞中,SR31747A在δ8-δ7甾醇异构酶步骤抑制了胆固醇生物合成。这一观察结果与伊莫帕明结合蛋白在动物细胞胆固醇生物合成途径中作为甾醇异构酶的作用一致。相比之下,尽管该蛋白与酵母甾醇异构酶结构相似,但没有证据表明西格玛1受体具有这种作用。我们发现,SR31747A在纳摩尔浓度下对各种已建立的细胞系也具有抗增殖作用。SR31747A的抗增殖活性可被胆固醇逆转。甾醇异构酶的过量表达增强了CHO细胞的抗性。最后这一观察结果强烈表明,甾醇异构酶与该药物在已建立细胞系中的抗增殖作用有关。